Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses

Glioblastoma multiforme (GBM) is the most common adult primary brain malignancy, with dismal survival rates of ~14.6 months. The current standard-of-care consists of surgical resection and chemoradiotherapy, however the treatment response is limited by factors such as tumour heterogeneity, treatment...

Full description

Bibliographic Details
Main Authors: Jennifer Moran, Eimear Mylod, Laura E. Kane, Caroline Marion, Emily Keenan, Marianna Mekhaeil, Joanne Lysaght, Kumlesh K. Dev, Jacintha O’Sullivan, Melissa J. Conroy
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Pharmaceutics
Subjects:
NK cells
Glioblastoma multiforme
immunotherapy
Olaparib
PARP Inhibitor
Online Access:https://www.mdpi.com/1999-4923/15/2/360

Internet

https://www.mdpi.com/1999-4923/15/2/360

Similar Items